SCHEMBL6946378

SCHEMBL6946378

O=C(NCc1ccc(-c2ccccc2)cc1)c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
HPGD P15428 2/20 0.51
CYP2C19 P33261 2/20 0.51
MAPT P10636 3/20 0.50
ALDH1A1 P00352 2/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
ACKR3 P25106 1/20 0.49
ADAMTS5 Q9UNA0 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
AKR1C3 P42330 1/20 0.47
EPHX2 P34913 1/20 0.47
NR1H4 Q96RI1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944295 0.93 MEN1 (0.58) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL6942032 0.87 FFAR1 (0.58) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL6941766 0.85 MEN1 (0.54) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL6942084 0.83 MMP13 (0.57) MEN1KMT2ASMN1; SMN2CYP3A4MAPT
SCHEMBL6939616 0.82 MEN1 (0.51) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL6943714 0.82 HPGD (0.46) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL6819599 0.82 MAPT (0.64) MEN1KMT2ASMN1; SMN2CYP1A2HPGD
SCHEMBL6940041 0.82 MEN1 (0.54) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL7605514 0.80 GALR3 (0.56) KMT2ASMN1; SMN2CYP1A2CYP2C19ALDH1A1
SCHEMBL6940724 0.80 MEN1 (0.61) MEN1KMT2ASMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MEN1 2660/4885KMT2A 1991/4885SMN1; SMN2 3616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.